TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02441894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL XRP6258
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-G-CSF
Description: Pharmaceutical form:solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine or Diphenhydramine
Description: Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide, Granisetron, or Ondansetron
Description: Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
Study: NCT02361892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulipristal acetate
Description: 5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
Study: NCT02882698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Down Syndrome Group 1
Description: Acquisition and retention phase on maze A, transfer on maze B and C.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Down Syndrome Group 2
Description: Acquisition and retention phase on maze C, transfer on maze A and B.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical Development Group 1
Description: Control group. Acquisition and retention phase on maze A, transfer on maze B and C.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Typical Development Group 2
Description: Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
Study: NCT00176839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
Study: NCT02664857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
Study: NCT00176839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be administered to umbilical cord blood recipients.
Study: NCT01227876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ster
Description: prednisolone 1% ophthalmic suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Fort
Description: prednisolone 1% ophthalmic suspension
Study: NCT04366908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT + Calcifediol
Description: The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS) plus Calcifediol caps. 266 µg. According to the pharmacokinetics of Calcifediol evaluated in an inflammatory model, the posology will be~Start: 2 capsules Days 3, 7, 14, 21, 28: 1 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT
Description: The subject will be treated with the best available therapy, which will include any combination of drugs included in the current protocol of the Ministry of Health and/or complementary notes issued by the Spanish Agency of Medicines and Health Products (AEMPS).
Study: NCT03378141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal Nutrition Behavior change
Description: Counseling and community mobilization
Study: NCT00158769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous GR270773 - Phospholipid emulsion
Description: GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous GR270773 - Phospholipid emulsion
Description: GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
Study: NCT01897155

Intervention type: OTHER
Group type: OTHER
Intervention: SBP 20-30% over baseline
Description: Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
Study: NCT00271544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing Lead
Description: implant and follow-up of study device
Study: NCT01685684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx
Description: 40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, divided into 2 doses, q12h
Study: NCT01897155

Intervention type: OTHER
Group type: OTHER
Intervention: SBP 20-30% under baseline
Description: Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
Study: NCT03532243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incremental inspiratory load
Description: inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: incremental inspiratory load
Description: inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
Study: NCT03230942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-operative education
Description: Verbal and booklet about symptoms and physical conditions pos knee replacement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pos-operative rehabilitation
Description: Physical therapy treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pos-operative rehabilitation
Description: Physical therapy treatment
Study: NCT03107676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk extensors endurance training
Description: endurance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk extensors endurance training
Description: endurance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: trunk extensors endurance training
Description: endurance training
Study: NCT00004095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT02311699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to reduce IPV and HIV
Description: The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to reduce IPV and HIV
Description: The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to reduce IPV and HIV
Description: The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two-hour session per group of participants.
Study: NCT02557360

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine
Description: Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
Study: NCT01523561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dance group
Description: The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged.
Study: NCT02404883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Decision-Aid Tool
Study: NCT00797797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Treatment Added
Description: No added treatment
Study: NCT01457469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: Receive nicotine replacement patches

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive enhanced quitline intervention
Study: NCT01786668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg
Description: 4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg
Description: 4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Description: 4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
Study: NCT00797797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran Added
Description: Milnacipran 100 mg/d added
Study: NCT01056341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
Study: NCT01472731

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 89Zr-GC1008
Description: radioactive labeled GC1008, intravenous use, 37 MBq total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 5 mg/kg intravenous use
Study: NCT02664857

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Group P will not take orally during 12 weeks. This group will only observe by researchers.
Study: NCT01882920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goal Directed Intravenous Restrictive Fluid Therapy
Description: Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) \<2.5 l/min/m2, stroke volume index (SVI) \< 35 SVI ml/m2 and stroke volume variation (SVV)\> 15%. In the case of CI \<2.5 l/min/m2 and SVI \<35 ml/m2 with SVV \< 15%, an infusion with dopamine was initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Intravenous Fluid therapy
Description: Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
Study: NCT06166316

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: overdenture retained by locator attachments.
Description: • Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: overdenture retained by locator attachments.
Description: • Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: overdenture retained by locator attachments.
Description: • Implant-retained overdenture construction procedures:~1. Primary maxillary and mandibular impressions were made, and custom trays were fabricated using auto-polymerizing acrylic resin.~2. Definitive impressions were made with non-eugenol zinc oxide paste, and the impression copings were threaded to the implants, and polyether material was injected around the copings through the opening of the tray. Auto-polymerizing acrylic resin was used to pick up the copings with the tray. Implant analogs were screwed to the copings and the impressions was poured with stone.~3. Locator abutment (Dentium, Co. Ltd., Korea) screwed in the analogs. Jaw relations were recorded, and semi-anatomical acrylic teeth eeee arranged in balanced occlusion.~4. The locator housing and retentive clips were incorporated into the fitting surface of the overdentures during denture processing.
Study: NCT02727608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
Study: NCT01056341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo for 6 months
Study: NCT05752565

Intervention type: DEVICE
Group type: OTHER
Intervention: SenseWear armband device
Description: Device: SenseWear armband device Metabolic Holter, Physical Activity and Lifestyle, Portable outpatient multi-sensor energy consumption in calories (EE), movement, physical activity, quality of life
Study: NCT03914235

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tumescent Anesthesia
Description: A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic tourniquet
Description: Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open release of the tendon
Description: Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open release of the tendon
Description: Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.
Study: NCT00571194

Intervention type: DRUG
Group type: OTHER
Intervention: pravastatin
Description: A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study
Study: NCT02689063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxigesic IV
Description: IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ibuprofen
Description: IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
Study: NCT03603938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium losartan
Description: treated with bedtime or awakening doses of potassium losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium losartan
Description: treated with bedtime or awakening doses of potassium losartan
Study: NCT00136578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-715992
Description: SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
Study: NCT01949753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure therapy with pharmacological facilitation
Description: Exposure with response prevention and pharmacological facilitation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exposure therapy
Description: Exposure with response prevention without pharmacological facilitation
Study: NCT01083017

Intervention type: DRUG
Intervention: chlorthalidone
Description: chlorthalidone 25mg/d vs. chlorthalidone 50mg/d